# Evommune, Inc. (EVMN)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/evommune-inc/ JSON: https://steadybase.io/company/evommune-inc.json Checked Nov 10, 2026. Latest filing read: Aug 6, 2026.

## Company

- Legal name: Evommune, Inc.
- Ticker: EVMN (NYSE)
- SEC CIK: 0002044725
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Palo Alto, CA
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: evommune.com
- Investor relations: https://ir.evommune.com
- LinkedIn: https://www.linkedin.com/company/evommune
- Next earnings date: Dec 10, 2026

## Key facts

- Revenue: $13.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/0001193125-26-093932-index.html
- Operating income: -$81.1M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/0001193125-26-093932-index.html
- Net income: -$68.9M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/0001193125-26-093932-index.html
- SG&A: $20.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/0001193125-26-093932-index.html
- Employees: 48 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm
- Shares outstanding: 36,292,113 as of Aug 4, 2026 (10-Q filed Aug 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/0001193125-26-337984-index.html
- Auditor: Bdo Usa, P.C, New York, NY, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm

## Business

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $13.0M | -$81.1M | -$68.9M | $20.0M |
| Dec 31, 2024 | $7.0M | -$70.0M | -$66.8M | $12.8M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/evommune-inc.json

## Officers and directors

- Luis C. Pena, President & CEO. Source: Form 4 filed Jun 24, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000162054826000007/0001620548-26-000007-index.htm
- Kyle Carver, Chief Financial Officer. LinkedIn: https://linkedin.com/in/kyle-carver-093b1939. Source: Form 4 filed Jul 10, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000175707226000007/0001757072-26-000007-index.htm
- Janice Suzann Drew, Chief of Dev. Operations. Source: Form 4 filed Jun 24, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000209105326000005/0002091053-26-000005-index.htm
- Jeegar Pravinkumar Patel, Chief Scientific Officer. Source: Form 4 filed Jun 24, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000209201726000007/0002092017-26-000007-index.htm
- Gregory S. Moss, Chief Business & Legal Officer. Source: Form 4 filed Jun 1, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000174249626000005/0001742496-26-000005-index.htm
- Eugene Bauer, Chief Medical Officer. LinkedIn: https://linkedin.com/in/eugene-bauer-2ab88610. Source: Form 4 filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000167862026000003/0001678620-26-000003-index.htm
- Arthur Kirsch, Director. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm
- David E. Cohen, Director. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm
- Derek DiRocco, Director. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm
- Eugene A. Bauer, Director. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm
- Felice Verduyn-van Weegen, Director. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm
- Rob Hopfner, Director. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm

## Recent 8-K events

- Nov 5, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526448443/evmn-20261105.htm
- Nov 4, 2026: Item 1.01, Entry into a material definitive agreement; Item 3.02, Unregistered sales of equity securities; Item 7.01, Regulation FD disclosure; Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-20261104.htm
- Oct 1, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526409865/evmn-20261001.htm
- Sep 23, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526399378/evmn-20260923.htm
- Sep 15, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526391390/evmn-20260915.htm
- Sep 9, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/evmn-20260908.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526337964/evmn-20260806.htm
- Jul 30, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526324972/evmn-20260731.htm
- Jun 29, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526286918/evmn-20260629.htm
- Jun 2, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/2044725/000119312526253482/evmn-20260602.htm

## Insider trades (Form 4)

- Jul 8, 2026: Kyle Carver (Chief Financial Officer) bought 1,000 shares, about $13,260. Source: https://www.sec.gov/Archives/edgar/data/2044725/000175707226000007/0001757072-26-000007-index.htm
- Jul 7, 2026: Arthur S. Kirsch (Director) bought 10,000 shares, about $133,000. Source: https://www.sec.gov/Archives/edgar/data/2044725/000129097626000004/0001290976-26-000004-index.htm
- Jun 22, 2026: Jeegar Pravinkumar Patel (Chief Scientific Officer) sold 1,488 shares, about $33,480. Source: https://www.sec.gov/Archives/edgar/data/2044725/000209201726000007/0002092017-26-000007-index.htm
- Jun 22, 2026: Janice Suzann Drew (Chief of Dev. Operations) sold 20,000 shares, about $452,600. Source: https://www.sec.gov/Archives/edgar/data/2044725/000209105326000005/0002091053-26-000005-index.htm
- Jun 22, 2026: Luis C. Pena (President & CEO) sold 7,438 shares, about $168,917. Source: https://www.sec.gov/Archives/edgar/data/2044725/000162054826000007/0001620548-26-000007-index.htm
- Jun 2, 2026: David E. Cohen (Director) sold 6,056 shares, about $123,094. Source: https://www.sec.gov/Archives/edgar/data/2044725/000134738326000003/0001347383-26-000003-index.htm
- Jun 1, 2026: Jeegar Pravinkumar Patel (Chief Scientific Officer) sold 16,687 shares, about $379,462. Source: https://www.sec.gov/Archives/edgar/data/2044725/000209201726000005/0002092017-26-000005-index.htm
- Jun 1, 2026: Luis C. Pena (President & CEO) sold 16,787 shares, about $381,736. Source: https://www.sec.gov/Archives/edgar/data/2044725/000162054826000005/0001620548-26-000005-index.htm
- May 28, 2026: Kyle Carver (Chief Financial Officer) sold 18,175 shares, about $415,117. Source: https://www.sec.gov/Archives/edgar/data/2044725/000175707226000005/0001757072-26-000005-index.htm
- May 28, 2026: Gregory S. Moss (Chief Business & Legal Officer) sold 14,223 shares, about $324,711. Source: https://www.sec.gov/Archives/edgar/data/2044725/000174249626000005/0001742496-26-000005-index.htm
- Dec 19, 2025: Robert Lorne Hopfner (Director) bought 1,000 shares, about $17,350. Source: https://www.sec.gov/Archives/edgar/data/2044725/000101297525000937/0001012975-25-000937-index.htm
- Nov 7, 2025: Weegen Felice Isabel Verduyn-van (Director) bought 1,562,500 shares, about $25.0M. Source: https://www.sec.gov/Archives/edgar/data/2044725/000209494125000004/0002094941-25-000004-index.htm
- Nov 7, 2025: Capital Management L.P. Ra (Director) bought 1,250,000 shares, about $20.0M. Source: https://www.sec.gov/Archives/edgar/data/2044725/000134682425000049/0001346824-25-000049-index.htm

## Latest filings

- 8-K filed Oct 1, 2026: https://www.sec.gov/Archives/edgar/data/2044725/000119312526409865/evmn-20261001.htm
- 10-K filed Mar 5, 2026: https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/evmn-20260630.htm
- DEF 14A filed Apr 21, 2026: https://www.sec.gov/Archives/edgar/data/2044725/000119312526166747/evmn-20260421.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/